Cosmo Pharmaceuticals N.V (C43) — Cash Flow Quality Index
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow Quality Index of 1.60x as of June 2022. Operating cash flow of €6.28 Million exceeds net income of €3.94 Million, indicating high earnings quality where cash backs reported profits. Explore Cosmo Pharmaceuticals N.V debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cosmo Pharmaceuticals N.V Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Cosmo Pharmaceuticals N.V across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see C43 cash generation efficiency.
Annual Cash Flow Quality Index for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year earnings quality comparison for Cosmo Pharmaceuticals N.V.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.22x | €162.41 Million | €133.24 Million | ▼ -95.8% |
| 2023 | 29.31x | €33.62 Million | €1.15 Million | ▲ +1419.7% |
| 2022 | 1.93x | €33.23 Million | €17.23 Million | ▲ +231.5% |
| 2021 | 0.58x | €12.61 Million | €21.67 Million | ▼ -48.1% |
| 2016 | 1.12x | €21.69 Million | €19.34 Million | — |